MLN4924 (1), which is in clinical trials as an anticancer agent, was 
stereoselectively synthesized from d-ribose via a route involving 
stereoselective reduction, regioselective cleavage of an isopropylidene moiety, 
and selective displacement of a cyclic sulfate moiety as key steps.